In this way, RUNX2, CXCR3 or GATA2 seem to be major players of progression and metastatic dissemination in PCa [38–43] whereas MXI1 has been recently identified as a new biomarker of aggressive disease [44]. Here, CXCR3 is linked to posterior cortical atrophy.